Day One Biopharmaceuticals, Inc. Quarterly Deferred Income Tax Expense (Benefit) in USD for Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Day One Biopharmaceuticals, Inc. quarterly Deferred Income Tax Expense (Benefit) history and growth rate for Q3 2024.
  • Day One Biopharmaceuticals, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $900K.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $900K Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.